December 2016
-
Gilead, Seattle, WA. Reporting to the Director, Respiratory Pharmaceutical Development, the successful candidate will play a number of key roles in the development of Gilead’s respiratory products. The successful candidate will be a member of… Read more . . .
-
An article by Johns Hopkins researchers published in the BMJ, the British Medical Journal, suggests that patients using the Respimat tiotropium soft mist inhaler for the treatment of COPD are 52% more likely to die… Read more . . .
-
The UK site where Pfizer has performed inhalation R&D is now on the market as “Discovery Park.” The company announced the closing of the site, which employed 2400 people, in February 2011. Although a representative… Read more . . .
-
According to Perrigo Company, which is partnered with Teva on a generic triamcinolone acetonide nasal spray, Teva has begun shipping the product. Perrigo developed the nasal spray, which is a generic equivalent of Sanofi’s Nasacort… Read more . . .
-
Hovione has announced the filing of an international patent for its new XCaps dry powder inhaler. According to the company, the XCaps DPI is “a device which only requires two steps to inhalation and which… Read more . . .
-
Sun Pharma Advanced Research Company (SPARC) has announced completion of Phase 3 studies for a new dry powder inhaler and its intention to launch a product based on the novel DPI in India by the… Read more . . .
-
Dry powder inhalation drug developer Savara Pharmaceuticals has graduated from the Austin Techonology Incubator (ATI) Bioscience Incubator, according to ATI. Savara, which was founded in 2007, is preparing for Phase 1 trials of its lead… Read more . . .
-
The Walter and Eliza Hall Institute (WEHI), Melbourne, Australia, has announced successful demonstration of proof of principle for a nasal spray vaccine to prevent type 1 diabetes. The research, conducted by scientists from WEHI and… Read more . . .
-
At the European Cystic Fibrosis Conference in Hamburg, Germany, Insmed presented data showing that Arikace liposomal amikacin for inhalation improved lung function in CF patients over six cycles of treatment. Each cycle included 28 days… Read more . . .
-
GlaxoSmithKline plans to expand its manufacturing facility in Mississauga, Ontario, in part to enable production of Relenza zanamivir dry powder for inhalation. The expansion is expected to create 70 new jobs. GSK will contribute more… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland